Rhythm Pharmaceuticals Inc Revenue Growth Rates (RYTM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Rhythm Pharmaceuticals Inc   (NASDAQ: RYTM)
 

RYTM's Revenue Growth by Quarter and Year

Rhythm Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RYTM Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 71.26
1st Quarter March 60.11
FY 131.37

RYTMs Annual Revenue
Rhythm Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 189.76 millions
Rhythm Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 130.13 millions
Rhythm Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 77.43 millions
Rhythm Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 23.64 millions
Rhythm Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 3.15 millions




RYTM Revenue second quarter 2026 Y/Y Growth Comment
Rhythm Pharmaceuticals Inc reported Revenue rise of 46.92% year on year in the second quarter 2026, to $ 71.26 millions, this is lower than Rhythm Pharmaceuticals Inc 's recent average Revenue surge of 277.3%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 98 other companies have achieved higher Revenue growth. While Rhythm Pharmaceuticals Inc ' s Revenue jump of 46.92% ranks overall at the positon no. 1925 in the second quarter 2026.


RYTM Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 36.86 % 72.64 % 175.65 %
3rd Quarter September - 54.29 % 47.78 % 425.7 %
2nd Quarter June 46.92 % 66.78 % 51.3 % 732.03 %
1st Quarter March 83.82 % 25.91 % 126.42 % 664.67 %
FY   - 45.82 % 68.08 % -

Financial Statements
Rhythm Pharmaceuticals Inc 's second quarter 2026 Revenue $ 71.26 millions RYTM's Income Statement
Rhythm Pharmaceuticals Inc 's second quarter 2025 Revenue $ 48.50 millions Quarterly RYTM's Income Statement


RYTM Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 11.6 % 25.8 % 7.69 %
3rd Quarter September - 5.77 % 14.34 % 17.07 %
2nd Quarter June 18.54 % 48.32 % 11.98 % 67.57 %
1st Quarter March 5 % -21.83 % 7.18 % 30.49 %
FY (Year on Year)   - 45.82 % 68.08 % -


Back to RYTM Growth rate Comparisons >> Back to RYTM Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #99
Healthcare Sector #295
Overall #1925

Revenue Y/Y Growth Statistics
High Average Low
980.5 % 277.3 % 45.83 %
(Mar 31 2023)   (Dec 31 2025)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #99
Healthcare Sector #295
Overall #1925
Revenue Y/Y Growth Statistics
High Average Low
980.5 % 277.3 % 45.83 %
(Mar 31 2023)   (Dec 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Rhythm Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
682.86 % 71.98 % -21.82 %
(Jun 30 2021)  


RYTM's II. Quarter Q/Q Revenue Comment
Rhythm Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue jump of 18.54% quarter on quarter, to $ 71.26 millions.

Within Major Pharmaceutical Preparations industry 48 other companies have achieved higher Revenue quarter on quarter growth. While Rhythm Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 526.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #100
Overall #526
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #100
Overall #526
Revenue Q/Q Growth Statistics
High Average Low
682.86 % 71.98 % -21.82 %
(Jun 30 2021)  


RYTM's II. Quarter Q/Q Revenue Comment
Rhythm Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue jump of 18.54% quarter on quarter, to $ 71.26 millions.

Within Major Pharmaceutical Preparations industry 48 other companies have achieved higher Revenue quarter on quarter growth. While Rhythm Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 526.


Rhythm Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 239.92 $ 217.17 $ 189.76 $ 174.33 $ 156.29
Y / Y Revenue Growth (TTM) 53.51 % 58.67 % 45.83 % 54.92 % 53.55 %
Year on Year Revenue Growth Overall Ranking # 312 # 73 # 64 # 50 # 55
Seqeuential Revenue Change (TTM) 10.48 % 14.44 % 8.85 % 11.55 % 14.19 %
Seq. Revenue Growth (TTM) Overall Ranking # 1925 # 1170 # 650 # 648 # 455


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Rhythm Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 240 millions, company would post below average annual Revenue growth of 14.19% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Rhythm Pharmaceuticals Inc 's Revenue growth from the 60.11% growth in Mar 31 2026.

In the Healthcare sector 87 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 73 to 312.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 99
Healthcare Sector # 88
Overall # 312

Revenue TTM Y/Y Growth Statistics
High Average Low
980.5 %
 277.3 %
45.83 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 99
Sector # 295
S&P 500 # 1925
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Rhythm Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 240 millions, company would post below average annual Revenue growth of 45.83% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Rhythm Pharmaceuticals Inc 's Revenue growth from the 60.11% growth in Mar 31 2026.

In the Healthcare sector 87 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 73 to 312.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 99
Healthcare Sector # 88
Overall # 312

Revenue TTM Y/Y Growth Statistics
High Average Low
980.5 %
277.3 %
45.83 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 99
Sector # 295
S&P 500 # 1925




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
RYTM's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions


About Rhythm Pharmaceuticals Inc Revenue Growth Rates (RYTM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Rhythm Pharmaceuticals Inc (CIK 1649904).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-052533
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Rhythm Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.